文献速递冠心病血脂与心血管预防

GUCY1A3冠心病风险位点的功能特征研究

Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus.
PubMed 文献 · Circulation · 2017-05-09

该研究探讨4q32.1染色体位点GUCY1A3与冠心病风险的关联机制。rs7692387风险等位基因携带者全血GUCY1A3 mRNA水平显著降低,转录因子ZEB1优先结合非风险等位基因并增加GUCY1A3表达。血小板和血管平滑肌细胞实验及小鼠数据表明sGC表达增高与动脉粥样硬化风险降低相关。

要点

  • rs7692387风险等位基因与全血GUCY1A3 mRNA水平降低相关。
  • ZEB1优先结合非风险等位基因,增加GUCY1A3启动子活性和表达。
  • 非风险等位基因携带者的血小板对NO供体和PDE5抑制剂的抗聚集作用增强。

核心结论

  • rs7692387位于一个内含子位点,可调节GUCY1A3启动子活性。
  • ZEB1优先结合非风险等位基因,导致GUCY1A3表达增加、sGC水平升高及刺激后sGC活性增高。
  • 人类和小鼠数据将sGC表达增高与较低的动脉粥样硬化风险相关联。

研究设计与样本

  • 研究采用基因表达和蛋白表达分析、计算机模拟分析、报告基因实验、siRNA敲低和过表达实验、血管平滑肌细胞迁移实验和血小板聚集分析。
  • 研究还使用了Hybrid Mouse Diversity Panel小鼠模型。

主要发现

  • 全血GUCY1A3 mRNA水平在rs7692387风险等位基因纯合个体中显著降低。
  • 报告基因实验显示携带风险等位基因的构建体GUCY1A3启动子活性显著降低。
  • 计算机模拟分析将DNase I超敏位点定位到rs7692387,并预测ZEB1优先结合非风险等位基因,实验证实了这一点。
  • ZEB1敲低导致非风险等位基因启动子活性更大幅度降低,并显著降低内源性GUCY1A3表达。
  • 离体血小板实验中,非风险等位基因纯合携带者的血小板在NO供体硝普钠和PDE5抑制剂西地那非作用下,对ADP诱导的血小板聚集的抑制增强, compared with 风险等位基因纯合携带者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A chromosomal locus at 4q32.1 has been genome-wide significantly associated with coronary artery disease risk. The locus encompasses GUCY1A3, which encodes the α1 subunit of the soluble guanylyl cyclase (sGC), a key enzyme in the nitric oxide/cGMP signaling pathway. The mechanism linking common variants in this region with coronary risk is not known. METHODS: Gene expression and protein expression were analyzed with quantitative polymerase chain reaction and immunoblotting, respectively. Putative allele-specific transcription factors were identified with in silico analyses and validated via allele-specific quantification of antibody-precipitated chromatin fractions. Regulatory properties of the lead risk variant region were analyzed with reporter gene assays. To assess the effect of zinc finger E box-binding homeobox 1 transcription factor (ZEB1), siRNA-mediated knockdown and overexpression experiments were performed. Association of GUCY1A3 genotype and cellular phenotypes was analyzed with vascular smooth muscle cell migration assays and platelet aggregation analyses. RESULTS: Whole-blood GUCY1A3 mRNA levels were significantly lower in individuals homozygous for the lead (rs7692387) risk variant. Likewise, reporter gene assays demonstrated significantly lower GUCY1A3 promoter activity for constructs carrying this allele. In silico analyses located a DNase I hypersensitivity site to rs7692387 and predicted binding of the transcription factor ZEB1 rather to the nonrisk allele, which was confirmed experimentally. Knockdown of ZEB1 resulted in more profound reduction of nonrisk allele promoter activity and a significant reduction of endogenous GUCY1A3 expression. Ex vivo-studied platelets from homozygous nonrisk allele carriers displayed enhanced inhibition of ADP-induced platelet aggregation by the nitric oxide donor sodium nitroprusside and the phosphodiesterase 5 inhibitor sildenafil compared with homozygous risk allele carriers. Moreover, pharmacological stimulation of sGC led to reduced migration only in vascular smooth muscle cells homozygous for the nonrisk allele. In the Hybrid Mouse Diversity Panel, higher levels of GUCY1A3 expression correlated with less atherosclerosis in the aorta. CONCLUSIONS: Rs7692387 is located in an intronic site that modulates GUCY1A3 promoter activity. The transcription factor ZEB1 binds preferentially to the nonrisk allele, leading to an increase in GUCY1A3 expression, higher sGC levels, and higher sGC activity after stimulation. Finally, human and mouse data link augmented sGC expression to lower risk of atherosclerosis.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kessler T, Wobst J, Wolf B, et al. Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus. Circulation. 2017. PMID: 28487391. doi:10.1161/CIRCULATIONAHA.116.024152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。